Report: Lupin, other firms may bid for GSK's portfolio of 'mature' drugs

BALTIMORE — Lupin, along with certain U.S. drugmakers and private equity funds, might be making plans to bid for a selection of older drugs from GlaxoSmithKline, according to Reuters, which cited sources familiar with the dealings.



Assets up for sale could net anywhere between $3.5 to $5 billion, according to sources. Andrew Witt, GSK's chief executive, said in April that the company was reviewing its older products and in May, the group invited select firms to consider bidding on them.



There was no comment on the matter from officials at GSK. But an analyst in Mumbai, who chose not to be named in the report because the talks were still private, remarked that "a smallish Indian player can do very focused promotion ...  and gain scale with increased penetration. This has been Lupin's strategy thus far with its U.S. branded business."